21001

Wiggin and Dana LLP One City Place 185 Asylum Street Hartford, Connecticut 06103-3402

860.297.3700 860.525.9380 fax www.wiggin.com

> RECEIVED CENTRAL FAX CENTER

> > JAN 1 9 2007.

ertificate

JAN 3 0 2007

of Correction

WIGGIN AND DANA

Counsellors at Law

MSPTO-please sfaxon
MSPTO-previous faxon
MSPTO-please
MSPTO-previous faxon
MSPTO-please
MSPT

Telefax Transmittal

Date:

January 19, 2007

To / Company / Telefax:

Attention: Certificate of Correction Branch / U. S. Patent Office /

571,273,8300

From:

Todd E. Garabedian, Ph.D.

Telephone / Email:

860.297.3716 / tgarabedian@wiggin.com

Client / matter code:

10706 / 97

Please copy:

We will copy:

This message is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure. If the reader of this message is not the intended recipient or an employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error please notify us immediately by telephone and return the original

message to us by mail. Thank you.

Special Instructions

RE: U. S. Patent No. 7,153,997 B2 Attorney Docket No: 102698-102

Dear Sir: Please check the contents attached herewith and verify that the following items were enclosed by sending confirmation to the above-noted facsimile number.

Letter Re: Certificate of Correction (3 pages)

Certificate of Correction Form PTO/SB/44 (1 Page)

Please issue the requested Certificate of Correction to correct the last name of the third named inventor, and to correct a minor typographical error, as set forth in the attached Letter and Certificate. Please do not hesitate to contact me if you have any questions.

Thank you.

JAN 3 0 2007

4 page(s) following this page

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Patent No.

7,153,997 B2

CENTRAL FAX CENTER

Issue Date

December 26, 2006

JAN 1 9 2007

Based on Application of

NEERAJ GARG, ET AL. 10/520,902

Serial No. Filed

January 7, 2005

For

NOVEL COMPOUNDS

Examiner
Attorney Docket

S. Kumar 102698-102

Group Art Unit Confirmation No.

1621 4807

Customer No.

27267

CERTIFICATE OF MAILING

Todd E. Garabedian, Ph.D. Registration No. 39,197

Attorney for Patentee

LETTER RE: CERTIFICATE OF CORRECTION SUBMITTED UNDER 37 CFR §1.323

Certificate of Correction Branch Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Patentees submit herewith a Form PTO/SB/44 to correct the name of the third named

inventor of the above-identified U.S. Patent.

On the cover page of the Patent, at item (75) "Inventors", the name of the third named inventor, "Thomas Anders Wilson Ericsson", should be corrected to read: "Thomas Anders Wilson Norin."

By Notice of Recordation of Assignment Document dated December 4, 2006, the USPTO notified Patentees that inventor Norin's name had been corrected in the Assignment at Reel 018579, Frame 0678.

Additionally, a minor mistake of a clerical or typographical nature in the above-identified U.S. Patent is noted in the second line of claim 7 at column 39 of the Patent. The last word in column 39, "is", should be deleted from the second line of claim 7. The second and third lines of claim 7 will then correctly read as follows:

"said additional therapeutic agent is an anti-obesity agent selected from the group consisting of an aP2 inhibitor, a".

Patentees submit that the above-noted name correction and minor typographical error occurred in good faith, and that the proposed corrections do not involve changes in the above-identified patent as would constitute new matter or would require re-examination. Accordingly, Patentees respectfully request that a Certificate of Correction be issued.

The \$100 Certificate of Correction Fee, as required under 37 CFR §1.20(a), as well as any other charges associated with this request, may be charged to Deposit Account 23-1665.

Two copies of this request are enclosed.

JAN 3 0 2007

If the Office requires any additional information, kindly contact Patentees' representative at the telephone number below.

Respectfully submitted,

NEERAJ GARG, ET AL.

Date: 19 JAW 2007

Todd E. Garabedian, Ph.D. Attorney for Patentees Registration No. 39,197

WIGGIN AND DANA LLP One Century Tower New Haven, CT 06508 Telephone: (203) 498-4400 Facsimile: (203) 782-2889

\10706\97\54908.1

PTO/SB/44 (02-01)

Approved for use through 01/31/2004. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,153,997 B2

DATED

: December 26, 2006

INVENTOR(S): Neeraj Garg, Mahmoud Rahiml Ghadim, Thomas Anders Wilson Norin, Lars

Johan Malm and Denis Evan Ryono

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- 1. On the cover page of the Patent, at item (75) "Inventors", the name of the third named inventor, "Thomas Anders Wilson Ericsson", should be corrected to read: "Thomas Anders Wilson Norin."
- 2. In the second line of claim 7 at column 39 of the Patent, the last word in column 39, "is", should be deleted from the second line of claim 7. The second and third lines of claim 7 will then correctly read as follows:

"said additional therapeutic agent is an anti-obesity agent selected from the group consisting of an aP2 inhibitor, a".

MAILING ADDRESS OF SENDER: Todd E. Garabedian, Ph.D. Wiggin & Dana LLP

P. O. Box 1832

PATENT NO. 7,153,997 B2

No. of additional copies



New Haven, CT 06508-1832

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the emount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WD#54910

RECEIVED CENTRAL FAX CENTER

Ø 001

JAN 1 8 2007

Wiggin and Dana LLP One City Place 185 Asylum Street Hartford, Connecticut

06103-3402

860.297.3700 860.525.9380 fax www.wiggin.com Certificate
JAN 3 0 2007

of Correction

WIGGIN AND DANA

This message is intended for the use of the individual or entity to which it is addressed and may contain

information that is privileged, con-

fidential and exempt from disclosure. If the reader of this message is

not the intended recipient or an

employee or agent responsible for delivering the message to the intended recipient, you are hereby

notified that any dissemination, dis-

tribution or copying of this message is strictly prohibited. If you have received this communication in

error please notify us immediately

by telephone and return the original

message to us by mail. Thank you.

Counsellors at Law

Telefax Transmittal

Date:

January 19, 2007

To / Company / Telefax:

Attention: Certificate of Correction Branch / U. S. Patent Office /

571.273.8300

From:

Todd E. Garabedian, Ph.D.

Telephone / Email:

860.297.3716 / tgarabedian@wiggin.com

Client / matter code:

10706 / 97

Please copy:

We will copy:

Special Instructions

RE: U. S. Patent No. 7,153,997 B2 Attorney Docket No: 102698-102

Dear Sir: Please check the contents attached herewith and verify that the following items were enclosed by sending confirmation to the above-noted facsimile number.

- Letter Re: Certificate of Correction (3 pages)
- Certificate of Correction Form PTO/SB/44 (1 Page)

Please issue the requested Certificate of Correction to correct the last name of the third named inventor, and to correct a minor typographical error, as set forth in the attached Letter and Certificate. Please do not hesitate to contact me if you have any questions.

Thank you.

MAN 3 0 2007

.

RECEIVED CENTRAL FAX CENTER

JAN 1 9 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent No.

7,153,997 B2

Issue Date

December 26, 2006

Based on Application of

NEERAJ GARG, ET AL.

Serial No.

10/520,902

Filed

January 7, 2005

For

NOVEL COMPOUNDS

Examiner

S. Kumar

Attorney Docket

102698-102

Group Art Unit Confirmation No.

1621 4807

Customer No.

27267

CERTIFICATE OF MAILING

Todd E. Garabedian, Ph.D. Registration No. 39,197
Attorney for Patentee

LETTER RE: CERTIFICATE OF CORRECTION SUBMITTED UNDER 37 CFR §1.323

Certificate of Correction Branch Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Patentees submit herewith a Form PTO/SB/44 to correct the name of the third named

inventor of the above-identified U.S. Patent.

On the cover page of the Patent, at item (75) "Inventors", the name of the third named inventor, "Thomas Anders Wilson Ericsson", should be corrected to read: "Thomas Anders Wilson Norin."

By Notice of Recordation of Assignment Document dated December 4, 2006, the USPTO notified Patentees that inventor Norin's name had been corrected in the Assignment at Reel 018579, Frame 0678.

Additionally, a minor mistake of a clerical or typographical nature in the above-identified U.S. Patent is noted in the second line of claim 7 at column 39 of the Patent. The last word in column 39, "is", should be deleted from the second line of claim 7. The second and third lines of claim 7 will then correctly read as follows:

"said additional therapeutic agent is an anti-obesity agent selected from the group consisting of an aP2 inhibitor, a".

Patentees submit that the above-noted name correction and minor typographical error occurred in good faith, and that the proposed corrections do not involve changes in the above-identified patent as would constitute new matter or would require re-examination. Accordingly, Patentees respectfully request that a Certificate of Correction be issued.

The \$100 Certificate of Correction Fee, as required under 37 CFR §1.20(a), as well as any other charges associated with this request, may be charged to Deposit Account 23-1665.

Two copies of this request are enclosed.

If the Office requires any additional information, kindly contact Patentees' representative at the telephone number below.

Respectfully submitted,

NEERAJ GARG, ET AL.

Date: 19 JAN 2007

Todd E. Garabedian, Ph.D. Attorney for Patentees

Registration No. 39,197

WIGGIN AND DANA LLP One Century Tower New Haven, CT 06508

Telephone: (203) 498-4400 Facsimile: (203) 782-2889

\10706\97\54908.1

PTO/SB/44 (02-01)

Approved for use through 01/31/2004, OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless (I displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO

: 7,153,997 B2

DATED

: December 26, 2006

INVENTOR(S): Neeraj Garg, Mahmoud Rahimi Ghadim, Thomas Anders Wilson Norln, Lars

Johan Malm and Denis Evan Ryono

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- 1. On the cover page of the Patent, at item (75) "Inventors", the name of the third named inventor, "Thomas Anders Wilson Ericsson", should be corrected to read: "Thomas Anders Wilson Norin."
- 2. In the second line of claim 7 at column 39 of the Patent, the last word in column 39, "is", should be deleted from the second line of claim 7. The second and third lines of claim 7 will then correctly read as follows:

"said additional therapeutic agent is an anti-obesity agent selected from the group consisting of an aP2 inhibitor, a".

JAN 3 0 2007

MAILING ADDRESS OF SENDER:

Todd E. Garabedian, Ph.D. Wiggin & Dana LLP

P. O. Box 1832

PATENT NO. 6,633,175 B1

No, of additional copies



New Haven. CT 06508-1832

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WD#54910